PRDM9 and breast carcinoma: Moreover, the histone methyltransferase Smyd5 maintains breast cancer dormancy, and similarly the histone methylation inhibitor 5-azacytidine facilities maintenance in breast cancer and head and neck squamous cell carcinoma (HNSCC) [82, 83].